Does the media favor TSHA or HHH?

In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 4 articles in the media. Howard Hughes' average media sentiment score of 1.75 beat Taysha Gene Therapies' score of 0.85 indicating that Howard Hughes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Howard Hughes 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer RYTM or TSHA?

In the previous week, Rhythm Pharmaceuticals had 11 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 4 mentions for Taysha Gene Therapies. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Taysha Gene Therapies' score of 0.85 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ORKA or TSHA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -21.65% -20.88% Taysha Gene Therapies N/A -56.19% -41.84%

Does the media prefer ORKA or TSHA?

In the previous week, Oruka Therapeutics had 9 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 13 mentions for Oruka Therapeutics and 4 mentions for Taysha Gene Therapies. Oruka Therapeutics' average media sentiment score of 1.45 beat Taysha Gene Therapies' score of 0.85 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CGON or TSHA?

In the previous week, CG Oncology had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 7 mentions for CG Oncology and 4 mentions for Taysha Gene Therapies. CG Oncology's average media sentiment score of 1.37 beat Taysha Gene Therapies' score of 0.85 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TSHA or SRRK more profitable?

Taysha Gene Therapies' return on equity of -56.19% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.19% -41.84% Scholar Rock N/A -160.19% -87.18%

Does the media prefer TSHA or SRRK?

In the previous week, Scholar Rock had 6 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 10 mentions for Scholar Rock and 4 mentions for Taysha Gene Therapies. Scholar Rock's average media sentiment score of 1.33 beat Taysha Gene Therapies' score of 0.85 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Taysha Gene Therapies (TSHA) Competitors

$5.77 -0.19 (-3.19%)

As of 08/28/2026 04:00 PM Eastern

Compare

TSHA vs. HHH, RYTM, ORKA, CGON, and SRRK

Should you buy Taysha Gene Therapies stock or one of its competitors? Taysha Gene Therapies's main competitors and comparable companies include Howard Hughes (HHH), Rhythm Pharmaceuticals (RYTM), Oruka Therapeutics (ORKA), CG Oncology (CGON), and Scholar Rock (SRRK). Companies are selected based on similarities in market, industry, and size.

How does Taysha Gene Therapies compare to Howard Hughes?

Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Taysha Gene Therapies has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Howard Hughes has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Howard Hughes has a net margin of 12.31% compared to Taysha Gene Therapies' net margin of 0.00%. Howard Hughes' return on equity of 7.51% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Howard Hughes	12.31%	7.51%	2.41%

Taysha Gene Therapies presently has a consensus target price of $12.77, suggesting a potential upside of 121.30%. Howard Hughes has a consensus target price of $79.00, suggesting a potential upside of 21.91%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, equities analysts clearly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Howard Hughes	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	192.43	-$109M	-$0.42	N/A
Howard Hughes	$1.47B	2.62	$131.88M	$4.94	13.12

In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 4 articles in the media. Howard Hughes' average media sentiment score of 1.75 beat Taysha Gene Therapies' score of 0.85 indicating that Howard Hughes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Howard Hughes	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 93.8% of Howard Hughes shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 47.7% of Howard Hughes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Howard Hughes beats Taysha Gene Therapies on 10 of the 16 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Rhythm Pharmaceuticals currently has a consensus price target of $141.12, indicating a potential upside of 31.68%. Taysha Gene Therapies has a consensus price target of $12.77, indicating a potential upside of 121.30%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Rhythm Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Taysha Gene Therapies has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A
Taysha Gene Therapies	$9.77M	192.43	-$109M	-$0.42	N/A

Taysha Gene Therapies has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Taysha Gene Therapies' return on equity of -56.19% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Rhythm Pharmaceuticals had 11 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 4 mentions for Taysha Gene Therapies. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Taysha Gene Therapies' score of 0.85 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Taysha Gene Therapies beats Rhythm Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Oruka Therapeutics has a beta of -0.34, indicating that its stock price is 134% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

In the previous week, Oruka Therapeutics had 9 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 13 mentions for Oruka Therapeutics and 4 mentions for Taysha Gene Therapies. Oruka Therapeutics' average media sentiment score of 1.45 beat Taysha Gene Therapies' score of 0.85 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Oruka Therapeutics currently has a consensus price target of $134.30, indicating a potential upside of 47.36%. Taysha Gene Therapies has a consensus price target of $12.77, indicating a potential upside of 121.30%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Oruka Therapeutics has higher earnings, but lower revenue than Taysha Gene Therapies. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Taysha Gene Therapies	$9.77M	192.43	-$109M	-$0.42	N/A

Oruka Therapeutics' return on equity of -21.65% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Summary

Taysha Gene Therapies beats Oruka Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Taysha Gene Therapies compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, CG Oncology had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 7 mentions for CG Oncology and 4 mentions for Taysha Gene Therapies. CG Oncology's average media sentiment score of 1.37 beat Taysha Gene Therapies' score of 0.85 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,631.06	-$160.99M	-$2.69	N/A
Taysha Gene Therapies	$9.77M	192.43	-$109M	-$0.42	N/A

CG Oncology currently has a consensus target price of $83.18, suggesting a potential upside of 11.89%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 121.30%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Taysha Gene Therapies has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CG Oncology has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Summary

Taysha Gene Therapies beats CG Oncology on 10 of the 16 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Scholar Rock?

Taysha Gene Therapies (NASDAQ:TSHA) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Taysha Gene Therapies has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

In the previous week, Scholar Rock had 6 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 10 mentions for Scholar Rock and 4 mentions for Taysha Gene Therapies. Scholar Rock's average media sentiment score of 1.33 beat Taysha Gene Therapies' score of 0.85 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Taysha Gene Therapies' return on equity of -56.19% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Scholar Rock	N/A	-160.19%	-87.18%

Taysha Gene Therapies currently has a consensus target price of $12.77, indicating a potential upside of 121.30%. Scholar Rock has a consensus target price of $58.77, indicating a potential upside of 1.68%. Given Taysha Gene Therapies' higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

Taysha Gene Therapies has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	192.43	-$109M	-$0.42	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Summary

Taysha Gene Therapies beats Scholar Rock on 8 of the 14 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSHA vs. The Competition

Export

Metric	Taysha Gene Therapies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.88B	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-13.74	11.62	273.16	25.45
Price / Sales	192.43	1,315.05	614.81	86.98
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	4.85	16.53	12.98	6.14
Net Income	-$109M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-5.25%	-0.31%	0.13%	-0.80%
1 Month Performance	-1.87%	9.80%	7.08%	4.13%
1 Year Performance	97.60%	55.66%	24.67%	15.17%

Taysha Gene Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSHA Taysha Gene Therapies	2.6965 of 5 stars	$5.77 -3.2%	$12.77 +121.3%	+97.6%	$1.88B	$9.77M	N/A	180
HHH Howard Hughes	4.097 of 5 stars	$66.92 +0.6%	$79.00 +18.1%	-15.0%	$3.97B	$1.47B	13.55	608
RYTM Rhythm Pharmaceuticals	2.874 of 5 stars	$111.44 +1.3%	$142.44 +27.8%	+3.9%	$7.54B	$189.76M	N/A	140	Positive News Analyst Forecast Gap Down
ORKA Oruka Therapeutics	2.8896 of 5 stars	$102.42 -5.1%	$134.30 +31.1%	+515.8%	$7.15B	N/A	N/A	N/A	News Coverage Positive News
CGON CG Oncology	3.2391 of 5 stars	$78.23 -2.0%	$83.18 +6.3%	+177.2%	$7.07B	$4.04M	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TSHA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, RYTM, ORKA, CGON, and SRRK

How does Taysha Gene Therapies compare to Howard Hughes?

Summary

How does Taysha Gene Therapies compare to Rhythm Pharmaceuticals?

Summary

How does Taysha Gene Therapies compare to Oruka Therapeutics?

Summary

How does Taysha Gene Therapies compare to CG Oncology?

Summary

How does Taysha Gene Therapies compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, RYTM, ORKA, CGON, and SRRK

How does Taysha Gene Therapies compare to Howard Hughes?

Which has more risk and volatility, TSHA or HHH?

Is TSHA or HHH more profitable?

Do analysts rate TSHA or HHH?

Which has higher valuation and earnings, TSHA or HHH?

Does the media favor TSHA or HHH?

Do insiders & institutionals have more ownership in TSHA or HHH?

Summary

How does Taysha Gene Therapies compare to Rhythm Pharmaceuticals?

Do analysts rate RYTM or TSHA?

Which has more volatility & risk, RYTM or TSHA?

Which has higher valuation & earnings, RYTM or TSHA?

Is RYTM or TSHA more profitable?

Do insiders & institutionals believe in RYTM or TSHA?

Does the media prefer RYTM or TSHA?

Summary

How does Taysha Gene Therapies compare to Oruka Therapeutics?

Which has more risk and volatility, ORKA or TSHA?

Does the media prefer ORKA or TSHA?

Do institutionals & insiders believe in ORKA or TSHA?

Do analysts prefer ORKA or TSHA?

Which has stronger valuation & earnings, ORKA or TSHA?

Is ORKA or TSHA more profitable?

Summary

How does Taysha Gene Therapies compare to CG Oncology?

Does the media favor CGON or TSHA?

Which has better earnings and valuation, CGON or TSHA?

Do analysts recommend CGON or TSHA?

Is CGON or TSHA more profitable?

Do insiders & institutionals believe in CGON or TSHA?

Which has more risk & volatility, CGON or TSHA?

Summary

How does Taysha Gene Therapies compare to Scholar Rock?

Which has more risk and volatility, TSHA or SRRK?

Does the media prefer TSHA or SRRK?

Do insiders & institutionals believe in TSHA or SRRK?

Is TSHA or SRRK more profitable?

Do analysts rate TSHA or SRRK?

Which has better valuation and earnings, TSHA or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools